Literature DB >> 21476916

Cell death and nonalcoholic steatohepatitis: where is ballooning relevant?

Mariana Verdelho Machado1, Helena Cortez-Pinto.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common form of liver disease in the Western world. Progression to more aggressive forms of liver injury, such as nonalcoholic steatohepatitis (NASH) and cirrhosis, occurs in less than a third of affected subjects. Human data and both in vivo and in vitro models demonstrate that cell death, particularly apoptosis, is increased in NAFLD and NASH patients, suggesting that it is crucial in disease progression. Indeed, fatty acids - more specifically, saturated fatty acids - strongly induce hepatocyte apoptosis. In addition, hepatic steatosis renders hepatocytes more susceptible to apoptotic injury. Ballooned hepatocytes and Mallory-Denk bodies are important hallmarks of NASH and correlate with disease progression. There are complex correlations between ballooning, Mallory-Denk bodies and apoptosis through keratin metabolism and depletion, as well as through the endoplasmic reticulum stress response. Whether apoptosis may promote hepatocellular ballooning, or vice versa, will be discussed in this article.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21476916     DOI: 10.1586/egh.11.16

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  19 in total

1.  Evaluation of ballooned hepatocytes as a risk factor for future progression of fibrosis in patients with non-alcoholic fatty liver disease.

Authors:  Keisuke Kakisaka; Yuji Suzuki; Yudai Fujiwara; Tamami Abe; Miki Yonezawa; Hidekatsu Kuroda; Kazuyuki Ishida; Tamotsu Sugai; Yasuhiro Takikawa
Journal:  J Gastroenterol       Date:  2018-04-21       Impact factor: 7.527

Review 2.  The relevance of liver histology to predicting clinically meaningful outcomes in nonalcoholic steatohepatitis.

Authors:  Mangesh R Pagadala; Arthur J McCullough
Journal:  Clin Liver Dis       Date:  2012-06-27       Impact factor: 6.126

3.  Acidophil bodies in nonalcoholic steatohepatitis.

Authors:  Matthew M Yeh; Patricia Belt; Elizabeth M Brunt; Kris V Kowdley; Laura A Wilson; Linda Ferrell
Journal:  Hum Pathol       Date:  2016-02-01       Impact factor: 3.466

Review 4.  Non-alcoholic fatty liver disease: what the clinician needs to know.

Authors:  Mariana Verdelho Machado; Helena Cortez-Pinto
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

5.  The DNA damage checkpoint protein ATM promotes hepatocellular apoptosis and fibrosis in a mouse model of non-alcoholic fatty liver disease.

Authors:  Erin K Daugherity; Gabriel Balmus; Ahmed Al Saei; Elizabeth S Moore; Delbert Abi Abdallah; Arlin B Rogers; Robert S Weiss; Kirk J Maurer
Journal:  Cell Cycle       Date:  2012-05-15       Impact factor: 4.534

6.  Reduced lipoapoptosis, hedgehog pathway activation and fibrosis in caspase-2 deficient mice with non-alcoholic steatohepatitis.

Authors:  M V Machado; G A Michelotti; T de Almeida Pereira; J Boursier; L Kruger; M Swiderska-Syn; G Karaca; G Xie; C D Guy; B Bohinc; K R Lindblom; E Johnson; S Kornbluth; A M Diehl
Journal:  Gut       Date:  2014-07-22       Impact factor: 23.059

Review 7.  Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis.

Authors:  Robert F Schwabe; Ira Tabas; Utpal B Pajvani
Journal:  Gastroenterology       Date:  2020-02-08       Impact factor: 22.682

Review 8.  [Nuclear Her2 expression in hepatocytes in liver disease].

Authors:  P Döring; G M Pilo; D F Calvisi; F Dombrowski
Journal:  Pathologe       Date:  2017-11       Impact factor: 1.011

9.  Cyclooxygenase-2 promotes hepatocellular apoptosis by interacting with TNF-α and IL-6 in the pathogenesis of nonalcoholic steatohepatitis in rats.

Authors:  Qi Cheng; Ning Li; Mingquan Chen; Jianming Zheng; Zhiping Qian; Xinyu Wang; Chong Huang; Shuchang Xu; Guangfeng Shi
Journal:  Dig Dis Sci       Date:  2013-08-23       Impact factor: 3.199

10.  NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications.

Authors:  Geoffrey C Farrell; Derrick van Rooyen; Lay Gan; Shivrakumar Chitturi
Journal:  Gut Liver       Date:  2012-04-17       Impact factor: 4.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.